Author:
Matsui Kazuki,Takeuchi Susumu,Haruna Yuka,Yamane Miki,Shimizu Takahiro,Hatsuma Yoshiki,Shimono Norihito,Sunada Machiko,Hayakawa Masakane,Nishida Tomo,Ito Shusei,Ide Masashi,Seino Maki,Sugihara Masahisa,Minagawa Yasushi,Tachiki Hidehisa
Reference31 articles.
1. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability;Amidon;Pharm. Res.,1995
2. European Medicines Agency. Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/EWP/1401/98 Rev.1),2010
3. Guidance Document: Biopharmaceutics Classification System Based Biowaiver;Health Canada,2014
4. Guidance for Industry: Waiver of In-Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System,2017
5. BCS biowaivers: similarities and differences among EMA, FDA, and WHO requirements;Davit;AAPS J.,2016
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献